{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:29:37Z","timestamp":1786577377863,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dahod Breast Cancer Research Program at the Boston University Chobanian & Avedisian School of Medicine"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-24-1321373-01-ESED"],"award-info":[{"award-number":["RSG-24-1321373-01-ESED"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Karin Grunebaum Cancer Research Foundation"},{"name":"Susan G. Komen","award":["ASP231042218"],"award-info":[{"award-number":["ASP231042218"]}]},{"name":"Susan G. Komen","award":["SAC220228"],"award-info":[{"award-number":["SAC220228"]}]},{"name":"National Cancer Institute","award":["R01 CA284133"],"award-info":[{"award-number":["R01 CA284133"]}]},{"name":"National Cancer Institute","award":["U01 CA164974"],"award-info":[{"award-number":["U01 CA164974"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02317-5","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:55:06Z","timestamp":1780721706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension, use of antihypertensive medications and breast cancer survival among Black women"],"prefix":"10.1186","volume":"28","author":[{"given":"Mollie E.","family":"Barnard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo N.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne X.","family":"Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi Y.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"2317_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2317_CR2","unstructured":"National Center for Health Statistics. https:\/\/www.cdc.gov\/nchs\/hus\/data-finder.htm."},{"key":"2317_CR3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/ijc.24054","volume":"124","author":"D Braithwaite","year":"2009","unstructured":"Braithwaite D, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009;124:1213\u20139. https:\/\/doi.org\/10.1002\/ijc.24054.","journal-title":"Int J Cancer"},{"key":"2317_CR4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.294.14.1765","volume":"294","author":"CM Tammemagi","year":"2005","unstructured":"Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294:1765\u201372. https:\/\/doi.org\/10.1001\/jama.294.14.1765.","journal-title":"JAMA"},{"key":"2317_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-013-2521-2","volume":"139","author":"S Nechuta","year":"2013","unstructured":"Nechuta S, et al. Comorbidities and breast cancer survival: a report from the Shanghai Breast Cancer Survival Study. Breast Cancer Res Treat. 2013;139:227\u201335. https:\/\/doi.org\/10.1007\/s10549-013-2521-2.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR6","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/HYPERTENSIONAHA.124.23509","volume":"81","author":"JA Jacobs","year":"2024","unstructured":"Jacobs JA, et al. Use and cost patterns of antihypertensive medications in the united states from 1996 to 2021. Hypertension. 2024;81:2307\u201317. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23509.","journal-title":"Hypertension"},{"key":"2317_CR7","doi-asserted-by":"publisher","first-page":"e032197","DOI":"10.1161\/JAHA.123.032197","volume":"13","author":"PD Lin","year":"2024","unstructured":"Lin PD, et al. Trends of antihypertensive prescription among US adults from 2010 to 2019 and changes following treatment guidelines: analysis of multicenter electronic health records. J Am Heart Assoc. 2024;13:e032197. https:\/\/doi.org\/10.1161\/JAHA.123.032197.","journal-title":"J Am Heart Assoc"},{"key":"2317_CR8","doi-asserted-by":"publisher","unstructured":"Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006;48:846\u2013852. https:\/\/doi.org\/10.1161\/01.HYP.0000240931.90917.0c","DOI":"10.1161\/01.HYP.0000240931.90917.0c"},{"key":"2317_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10549-024-07263-4","volume":"206","author":"OW Scott","year":"2024","unstructured":"Scott OW, TinTin S, Cavadino A, Elwood JM. Beta-blocker use and breast cancer outcomes: a meta-analysis. Breast Cancer Res Treat. 2024;206:443\u201363. https:\/\/doi.org\/10.1007\/s10549-024-07263-4.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clbc.2023.05.014","volume":"23","author":"J Yang","year":"2023","unstructured":"Yang J, Zhang S, Jiang W. Impact of beta blockers on breast cancer incidence and prognosis. Clin Breast Cancer. 2023;23:664\u201371. https:\/\/doi.org\/10.1016\/j.clbc.2023.05.014. e621.","journal-title":"Clin Breast Cancer"},{"key":"2317_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000455143","volume":"92","author":"HY Kim","year":"2017","unstructured":"Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92:264\u20138. https:\/\/doi.org\/10.1159\/000455143.","journal-title":"Oncology"},{"key":"2317_CR12","doi-asserted-by":"publisher","unstructured":"Li C, Li T, Tang R, Yuan S, Zhang W. \u03b2-Blocker use is not associated with improved clinical outcomes in women with breast cancer: a meta-analysis. Biosci Rep. 2020;40. https:\/\/doi.org\/10.1042\/bsr20200721.","DOI":"10.1042\/bsr20200721"},{"key":"2317_CR13","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.esmoop.2021.100066","volume":"6","author":"R Caparica","year":"2021","unstructured":"Caparica R, et al. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open. 2021;6:100066. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100066.","journal-title":"ESMO Open"},{"key":"2317_CR14","doi-asserted-by":"publisher","first-page":"609901","DOI":"10.3389\/fphar.2021.609901","volume":"12","author":"Y Xie","year":"2021","unstructured":"Xie Y, et al. Association between antihypertensive medication use and breast cancer: a systematic review and meta-analysis. Front Pharmacol. 2021;12:609901. https:\/\/doi.org\/10.3389\/fphar.2021.609901.","journal-title":"Front Pharmacol"},{"key":"2317_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-022-01891-7","volume":"127","author":"LL L\u00f8fling","year":"2022","unstructured":"L\u00f8fling LL, et al. \u03b2-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. Br J Cancer. 2022;127:1086\u201396. https:\/\/doi.org\/10.1038\/s41416-022-01891-7.","journal-title":"Br J Cancer"},{"key":"2317_CR16","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10552-021-01485-3","volume":"32","author":"NC Lorona","year":"2021","unstructured":"Lorona NC, et al. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes Control. 2021;32:1375\u201384. https:\/\/doi.org\/10.1007\/s10552-021-01485-3.","journal-title":"Cancer Causes Control"},{"key":"2317_CR17","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1158\/1055-9965.Epi-20-0711","volume":"29","author":"EEE Santala","year":"2020","unstructured":"Santala EEE, et al. Angiotensin receptor blockers associated with improved breast cancer survival-a nationwide cohort study from Finland. Cancer Epidemiol Biomark Prev. 2020;29:2376\u201382. https:\/\/doi.org\/10.1158\/1055-9965.Epi-20-0711.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2317_CR18","doi-asserted-by":"publisher","first-page":"eadf1147","DOI":"10.1126\/scitranslmed.adf1147","volume":"15","author":"A Chang","year":"2023","unstructured":"Chang A, et al. Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Sci Transl Med. 2023;15:eadf1147. https:\/\/doi.org\/10.1126\/scitranslmed.adf1147.","journal-title":"Sci Transl Med"},{"key":"2317_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-013-2654-3","volume":"140","author":"E Botteri","year":"2013","unstructured":"Botteri E, et al. Therapeutic effect of \u03b2-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140:567\u201375. https:\/\/doi.org\/10.1007\/s10549-013-2654-3.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR20","doi-asserted-by":"publisher","first-page":"18640","DOI":"10.18632\/oncotarget.15553","volume":"8","author":"R Coulson","year":"2017","unstructured":"Coulson R, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017;8:18640\u201356. https:\/\/doi.org\/10.18632\/oncotarget.15553.","journal-title":"Oncotarget"},{"key":"2317_CR21","doi-asserted-by":"publisher","first-page":"112114","DOI":"10.1016\/j.yexcr.2020.112114","volume":"394","author":"F Rasha","year":"2020","unstructured":"Rasha F, et al. Renin angiotensin system inhibition attenuates adipocyte-breast cancer cell interactions. Exp Cell Res. 2020;394:112114. https:\/\/doi.org\/10.1016\/j.yexcr.2020.112114.","journal-title":"Exp Cell Res"},{"key":"2317_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","volume":"129","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129:549\u201356. https:\/\/doi.org\/10.1007\/s10549-011-1505-3.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR23","doi-asserted-by":"publisher","first-page":"549","DOI":"10.7150\/jca.6888","volume":"4","author":"YK Chae","year":"2013","unstructured":"Chae YK, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer. 2013;4:549\u201356. https:\/\/doi.org\/10.7150\/jca.6888.","journal-title":"J Cancer"},{"key":"2317_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/EDE.0000000000000814","volume":"29","author":"J Busby","year":"2018","unstructured":"Busby J, Mills K, Zhang SD, Liberante FG, Cardwell CR. Postdiagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study. Epidemiology. 2018;29:407\u201313. https:\/\/doi.org\/10.1097\/EDE.0000000000000814.","journal-title":"Epidemiology"},{"key":"2317_CR25","unstructured":"Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women\u2019s Health Study: a follow-up study for causes and preventions of illness. J Am Med Womens Assoc (1972). 1995;50:56\u201358."},{"key":"2317_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10549-012-2131-4","volume":"134","author":"JL Bosco","year":"2012","unstructured":"Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Cardiometabolic factors and breast cancer risk in U.S. black women. Breast Cancer Res Treat. 2012;134:1247\u201356. https:\/\/doi.org\/10.1007\/s10549-012-2131-4.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annepidem.2005.11.008","volume":"16","author":"Y Cozier","year":"2006","unstructured":"Cozier Y, et al. Racial discrimination and the incidence of hypertension in US black women. Ann Epidemiol. 2006;16:681\u20137. https:\/\/doi.org\/10.1016\/j.annepidem.2005.11.008.","journal-title":"Ann Epidemiol"},{"key":"2317_CR28","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.277.5328.918","volume":"277","author":"RJ Sampson","year":"1997","unstructured":"Sampson RJ, Raudenbush SW, Earls F. Neighborhoods and violent crime: a multilevel study of collective efficacy. Science. 1997;277:918\u201324. https:\/\/doi.org\/10.1126\/science.277.5328.918.","journal-title":"Science"},{"key":"2317_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","volume":"22","author":"JH Neo","year":"2007","unstructured":"Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol. 2007;22:577\u201384. https:\/\/doi.org\/10.1111\/j.1440-1746.2006.04797.x.","journal-title":"J Gastroenterol Hepatol"},{"key":"2317_CR30","doi-asserted-by":"publisher","first-page":"e1067744","DOI":"10.1080\/2162402X.2015.1067744","volume":"5","author":"S Shrestha","year":"2016","unstructured":"Shrestha S, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype. Oncoimmunology. 2016;5:e1067744. https:\/\/doi.org\/10.1080\/2162402X.2015.1067744.","journal-title":"Oncoimmunology"},{"key":"2317_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0014-5793(01)02377-8","volume":"495","author":"Y Fujimoto","year":"2001","unstructured":"Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495:197\u2013200. https:\/\/doi.org\/10.1016\/s0014-5793(01)02377-8.","journal-title":"FEBS Lett"},{"key":"2317_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1054\/bjoc.2001.2102","volume":"85","author":"E Rivera","year":"2001","unstructured":"Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer. 2001;85:1396\u20139. https:\/\/doi.org\/10.1054\/bjoc.2001.2102.","journal-title":"Br J Cancer"},{"key":"2317_CR33","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","volume":"11","author":"T Suganuma","year":"2005","unstructured":"Suganuma T, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res. 2005;11:2686\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1946.","journal-title":"Clin Cancer Res"},{"key":"2317_CR34","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.1073\/pnas.0900351106","volume":"106","author":"DR Rhodes","year":"2009","unstructured":"Rhodes DR, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA. 2009;106:10284\u20139. https:\/\/doi.org\/10.1073\/pnas.0900351106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2317_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1023\/A:1024491219366","volume":"80","author":"TL Drell","year":"2003","unstructured":"Drell TL, t., et al. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat. 2003;80:63\u201370. https:\/\/doi.org\/10.1023\/A:1024491219366.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ijc.20410","volume":"112","author":"K Lang","year":"2004","unstructured":"Lang K, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer. 2004;112:231\u20138. https:\/\/doi.org\/10.1002\/ijc.20410.","journal-title":"Int J Cancer"},{"key":"2317_CR37","doi-asserted-by":"publisher","first-page":"eadq8279","DOI":"10.1126\/scisignal.adq8279","volume":"18","author":"T Lam","year":"2025","unstructured":"Lam T, et al. Hox-C12 coordinates beta(2)-adrenoceptor coupling to a cAMP\/calcium feedforward loop to drive invasion in triple-negative breast cancer. Sci Signal. 2025;18:eadq8279. https:\/\/doi.org\/10.1126\/scisignal.adq8279.","journal-title":"Sci Signal"},{"key":"2317_CR38","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.18632\/oncotarget.2460","volume":"5","author":"L Gargiulo","year":"2014","unstructured":"Gargiulo L, et al. Differential beta(2)-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget. 2014;5:10058\u201369. https:\/\/doi.org\/10.18632\/oncotarget.2460.","journal-title":"Oncotarget"},{"key":"2317_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10549-011-1348-y","volume":"130","author":"KS Madden","year":"2011","unstructured":"Madden KS, Szpunar MJ, Brown EB. beta-Adrenergic receptors (beta-AR) regulate VEGF and IL-6 production by divergent pathways in high beta-AR-expressing breast cancer cell lines. Breast Cancer Res Treat. 2011;130:747\u201358. https:\/\/doi.org\/10.1007\/s10549-011-1348-y.","journal-title":"Breast Cancer Res Treat"},{"key":"2317_CR40","doi-asserted-by":"publisher","first-page":"e113649","DOI":"10.1371\/journal.pone.0113649","volume":"9","author":"DQ Guo","year":"2014","unstructured":"Guo DQ, Zhang H, Tan SJ, Gu YC. Nifedipine promotes the proliferation and migration of breast cancer cells. PLoS ONE. 2014;9:e113649. https:\/\/doi.org\/10.1371\/journal.pone.0113649.","journal-title":"PLoS ONE"},{"key":"2317_CR41","first-page":"2413","volume":"52","author":"JM Taylor","year":"1992","unstructured":"Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res. 1992;52:2413\u20138.","journal-title":"Cancer Res"},{"key":"2317_CR42","doi-asserted-by":"publisher","first-page":"710978","DOI":"10.3389\/fphar.2021.710978","volume":"12","author":"YC Chen","year":"2021","unstructured":"Chen YC, et al. Nicardipine inhibits breast cancer migration via Nrf2\/HO-1 axis and matrix metalloproteinase-9 regulation. Front Pharmacol. 2021;12:710978. https:\/\/doi.org\/10.3389\/fphar.2021.710978.","journal-title":"Front Pharmacol"},{"key":"2317_CR43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.canlet.2008.03.032","volume":"267","author":"JT Taylor","year":"2008","unstructured":"Taylor JT, et al. Selective blockade of T-type Ca2\u2009+\u2009channels suppresses human breast cancer cell proliferation. Cancer Lett. 2008;267:116\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2008.03.032.","journal-title":"Cancer Lett"},{"key":"2317_CR44","doi-asserted-by":"publisher","first-page":"e2409310","DOI":"10.1002\/advs.202409310","volume":"12","author":"Y Sheng","year":"2025","unstructured":"Sheng Y, et al. Calcium channel blocker lacidipine promotes antitumor immunity by reprogramming tryptophan metabolism. Adv Sci (Weinh). 2025;12:e2409310. https:\/\/doi.org\/10.1002\/advs.202409310.","journal-title":"Adv Sci (Weinh)"},{"key":"2317_CR45","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fonc.2013.00211","volume":"3","author":"S Azzi","year":"2013","unstructured":"Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211. https:\/\/doi.org\/10.3389\/fonc.2013.00211.","journal-title":"Front Oncol"},{"key":"2317_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1517\/17425247.2011.558082","volume":"8","author":"NS Bhise","year":"2011","unstructured":"Bhise NS, Shmueli RB, Sunshine JC, Tzeng SY, Green JJ. Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv. 2011;8:485\u2013504. https:\/\/doi.org\/10.1517\/17425247.2011.558082.","journal-title":"Expert Opin Drug Deliv"},{"key":"2317_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1370\/afm.1398","volume":"10","author":"RG Roetzheim","year":"2012","unstructured":"Roetzheim RG, et al. Influence of primary care on breast cancer outcomes among medicare beneficiaries. Ann Fam Med. 2012;10:401\u201311. https:\/\/doi.org\/10.1370\/afm.1398.","journal-title":"Ann Fam Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02317-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02317-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:20:56Z","timestamp":1786576856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02317-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2317"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02317-5","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Boston University Medical Campus Institutional Review Board (IRB protocol number H-31535). Return of the baseline questionnaire implied informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"140"}}